FRANKLYN G. PRENDERGAST

Insider Reports History

Signature
/s/ Sandra Stoneman, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by FRANKLYN G. PRENDERGAST:

Company Role Class Num Shares Value Price $ Report Date Ownership
Immunome Inc. Director Common Stock 60,840 $359,564 $5.91 02 Oct 2023 Direct
Immunome Inc. Director Stock Option (Right to Buy) 137,725 02 Oct 2023 Direct
NeuBase Therapeutics, Inc. Director Stock option (right to buy) 37,600 09 Sep 2022 Direct
Lantern Pharma Inc. Director Stock Option (Right to Buy) 3,200 04 Nov 2021 Direct

Insider Reports Filed by FRANKLYN G. PRENDERGAST

Symbol Company Period Transactions Value $ Form Type Role Filing Time
IMNM Immunome Inc. 02 Oct 2023 2 $185,928 4 Director 04 Oct 2023, 17:28
IMNM Immunome Inc. 08 Jun 2023 1 $0 4 Director 12 Jun 2023, 16:51
NBSE NeuBase Therapeutics, Inc. 09 Sep 2022 1 $0 4 Director 12 Sep 2022, 17:01
IMNM Immunome Inc. 16 Jun 2022 1 $0 4 Director 21 Jun 2022, 18:03
LTRN Lantern Pharma Inc. 04 Nov 2021 1 $0 4 Director 08 Nov 2021, 15:05
NBSE NeuBase Therapeutics, Inc. 19 Aug 2021 1 $0 4 Director 17 Sep 2021, 16:17
IMNM Immunome Inc. 16 Jun 2021 1 $0 4 Director 21 Jun 2021, 20:07
IMNM Immunome Inc. 16 Jun 2021 0 $0 3 Director 21 Jun 2021, 20:05